Corvus Pharmaceuticals (CRVS) SEC Filings: History & Chart

Corvus Pharmaceuticals, Inc.(CRVS)

Biotechnology · South San Francisco, CA

$10.30-0.44 (-4.09%)

Delayed quote: Oct 6, 2026, 1:15 PM EDT

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

South San Francisco, CA

37 employees

www.corvuspharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Richard A. Miller

View full financials

Form	Filing Date	Accepted	Document
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
8-K	Jul 22, 2026	Jul 22, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
4	May 20, 2026	May 20, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
8-K	May 14, 2026	May 14, 2026	View filing
S-8	May 7, 2026	May 7, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
4	Apr 27, 2026	Apr 27, 2026	View filing
3	Apr 27, 2026	Apr 27, 2026	View filing
SC 13G/A	Apr 27, 2026	Apr 27, 2026	View filing
DEFA14A	Apr 24, 2026	Apr 24, 2026	View filing
DEF 14A	Apr 24, 2026	Apr 24, 2026	View filing
8-K	Apr 23, 2026	Apr 23, 2026	View filing
SC 13G/A	Mar 26, 2026	Mar 26, 2026	View filing
8-K	Mar 13, 2026	Mar 13, 2026	View filing
424B5	Mar 13, 2026	Mar 13, 2026	View filing
S-3ASR	Mar 13, 2026	Mar 13, 2026	View filing
10-K	Mar 12, 2026	Mar 12, 2026	View filing
8-K	Mar 12, 2026	Mar 12, 2026	View filing

SEC Filings

Recent Filings